Literature DB >> 2866789

Bronchial beta-adrenoceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects.

R Richards, A E Tattersfield.   

Abstract

The R-enantiomer of timolol, L-714,465, is considerably less potent as a beta 1- and beta 2-adrenoceptor antagonist in animals than timolol, whilst only slightly less potent in reducing intraocular pressure. If the same was true in man L-714,465 would have potential benefits over timolol in the treatment of glaucoma. The extent of bronchial beta-adrenoceptor blockade following one eyedrop in each eye of timolol 1% and L-714,465 1% was compared in six normal subjects, by measuring the displacement of the bronchodilator dose-response curve to isoprenaline following each drug compared to the isoprenaline dose-response curve after placebo eyedrops (methyl-cellulose). There was no significant difference between the dose-response curves to L-714,465 and placebo, but a significant displacement of the dose-response curve following timolol. The geometric mean dose ratio following timolol (21) differed significantly from that following L-714,465 (1.6). Heart rate at the end of the isoprenaline dose-response study was lower after timolol, despite the fact that subjects had received higher doses of isoprenaline. The trend was in the same direction after L-714,465 when compared with placebo though less marked. L-714,465 clearly causes less beta-adrenoceptor blockade than timolol when given as 1% eyedrops. The effects of L-714,465 1% on the airways and heart rate did not differ significantly from placebo in these six subjects but the pattern of response would be most consistent with L-714,465 having some beta-adrenoceptor blocking activity though considerably less than timolol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866789      PMCID: PMC1400720          DOI: 10.1111/j.1365-2125.1985.tb05097.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Respiratory effects of timolol.

Authors:  F T Fraunfelder; A F Barker
Journal:  N Engl J Med       Date:  1984-11-29       Impact factor: 91.245

2.  Plasma timolol levels after oral and intravenous administration.

Authors:  O F Else; H Sorenson; I R Edwards
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  Exacerbation of obstructive airway disease by timolol.

Authors:  F L Jones; N L Ekberg
Journal:  JAMA       Date:  1980-12-19       Impact factor: 56.272

4.  Timolol-induced bronchospasm in asthmatic bronchitis.

Authors:  R B Schoene; T R Martin; N B Charan; C L French
Journal:  JAMA       Date:  1981-04-10       Impact factor: 56.272

5.  Quantitative assessment of bronchial beta-adrenoceptor blockade in man.

Authors:  H R Gribbin; C J Baldwin; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

6.  Pathways of transepithelial potassium movement in the epithelium of distal colon in man.

Authors:  J C Kermode; C J Edmonds
Journal:  Clin Sci (Lond)       Date:  1980-07       Impact factor: 6.124

7.  Timolol eyedrop-induced severe bronchospasm.

Authors:  S Ostergaard Laursen; P Bjerrum
Journal:  Acta Med Scand       Date:  1982

8.  Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis.

Authors:  R B Schoene; T Abuan; R L Ward; C H Beasley
Journal:  Am J Ophthalmol       Date:  1984-01       Impact factor: 5.258

9.  Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man.

Authors:  A E Tattersfield; D J Cragg; R J Bacon
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

10.  Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.

Authors:  T W Wilson; W B Firor; G E Johnson; G I Holmes; M C Tsianco; P B Huber; R O Davies
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

View more
  6 in total

Review 1.  Clinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate.

Authors:  M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 2.  Chirality. Clinical pharmacokinetic and pharmacodynamic considerations.

Authors:  E J Lee; K M Williams
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 3.  Drug chirality and its clinical significance.

Authors:  A J Hutt; S C Tan
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects.

Authors:  R Richards; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

5.  Proceedings of the British Pharmacological Society. 17th-19th December 1986. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

6.  Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime--a new potential antiglaucoma agent.

Authors:  N Bodor; A Elkoussi
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.